New Long-Term Data for Genentech's Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)

– Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision –– Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months apart –– Detailed results from two global Phase III RVO studies will be presented at Angiogenesis, Exudation, a...

Related Keywords

Paris ,France General ,France ,Florida ,United States ,South San Francisco ,California ,Ramin Tadayoni ,Levi Garraway ,Bruno Eschli ,Loren Kalm ,Danielle Haney ,Shirley Dang ,Genentech ,Drug Administration ,Clinical Development Program ,Roche Group ,Global Product Development ,Bascom Palmer Eye Institute ,Global Product ,Paris Cit ,Retinal Vein Occlusion ,Clinical Development ,Important Safety Information ,Vabysmo Prescribing Information ,